ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.

Prostate Cancer Clinical Trial

Official title:

ODM-201 Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Non-progressive Disease After Subsequent Treatment With a Taxane: A Multicenter Randomized Double-blind Placebo-controlled Phase II Trial.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02933801
• Other study ID #: SAKK 08/16
• Secondary ID: 2016-003996-23
• Status: Terminated
• Phase: Phase 2
• Start date: March 31, 2017
• Est. completion date: November 15, 2023

Study information

• Verified date: March 2024
• Source: Swiss Group for Clinical Cancer Research
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main objective of the trial is to assess impact of maintenance therapy with ODM-201 on radiographic progression-free survival (rPFS) of patients with mCRPC pretreated with novel hormonal agents who have non-progressive disease after chemotherapy with a taxane.

Description:

The treatment of metastatic castration-resistant prostate cancer has evolved rapidly over the past few years. First line treatment with one of the novel antihormonal drugs abiraterone or enzalutamide followed by chemotherapy with docetaxel is now standard of care. If a patient has disease stabilization on chemotherapy he undergoes a watchful waiting period and further treatment is only started at the time of disease progression. This trial tests the immediate use of the novel androgen receptor antagonist ODM-201 as maintenance treatment after chemotherapy aiming at prolonging radiographic progression free survival as compared to watchful waiting.

The main objective of the trial is to assess impact of maintenance therapy with ODM-201 on radiographic progression-free survival (rPFS) of patients with mCRPC pretreated with novel hormonal agents who have non-progressive disease after chemotherapy with a taxane.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 92
• Est. completion date: November 15, 2023
• Est. primary completion date: June 28, 2021
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Written informed consent according to Swiss law and ICH/GCP regulations before registration and prior to any trial specific procedures not part of normal medical care.

• Histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate

• Castration resistance: tumor progression after orchiectomy or during treatment with GnRH analogues (agonists or antagonists)

• Metastatic disease, documented by imaging

• Total testosterone = 50 ng/dL (= 1.7 nmol/L)

• Treatment with abiraterone AND/OR enzalutamide for at least 8 weeks prior to taxane based chemotherapy

• No evidence of disease progression after chemotherapy with docetaxel (at least cumulative dose of = 300 mg/m2 or total dose = 600mg) or cabazitaxel (at least cumulative dose of = 80 mg/m2 or total dose = 160 mg)

• No evidence of progression on imaging according to PCWG3

• No evidence of progression on PSA levels referred to the nadir since start of taxane treatment (PSA progression defined as > 25% increase of PSA level or >50% if PSA decrease under chemotherapy >50% AND > 5 ng/mL increase in the absolute PSA value)

• Non-surgically castrated patient agrees on ongoing use of GnRH analogues (agonists or antagonists) during the trial

• Planned start of trial treatment 2 to 8 weeks after last taxane dose

• Male patient 18 years or older

• WHO performance status of =2

• Laboratory values as specified below

• alanine aminotransferase (ALT) = 2.5 x ULN (except for patients with liver metastases = 5.0 x ULN)

• Total bilirubin = 1.5 x ULN (except for patients with Gilbert's disease = 3.0 x ULN)

• Estimated creatinine clearance using the Cockcroft-Gault formula > 30 mL/minute

• Blood counts at screening: haemoglobin = 90 g/L, absolute neutrophil count = 1500/µl (1.5x109/L), platelet count = 100,000/µl (100x109/L) (patient must not have received any growth factor or blood transfusion within 7 days of the haematology laboratory obtained at screening)

• Adequate cardiac function: Left ventricular Ejection Fraction (LVEF) = 40% as determined by echocardiography (ECHO)

• Patient is able and willing to swallow trial drug as whole tablet

• Sexually active male subjects must agree to use condoms as an effective barrier method and refrain from sperm donation, and/or their female partners of reproductive potential to use a method of effective birth control, during the study treatment and for 3 months after the end of the treatment.

• Patient agrees to participate in the mandatory translational research project

Exclusion Criteria:

• Prior chemotherapy for prostate cancer except from chemotherapy with a taxane

• Concurrent disease requiring higher doses of corticosteroid than the equivalent of 10 mg prednisone per day

• Known CNS or leptomeningeal metastases

• Clinical or radiological evidence of current spinal cord compression

• History of hematologic or primary solid tumor malignancy, unless in remission for at least 2 years from registration with the exception of localized non-melanoma skin cancer or carcinoma in situ having undergone complete resection.

• Prior therapy for mCRPC with modern anti-hormonal treatment except for enzalutamide or abiraterone

• Concurrent treatment with other experimental drugs or treatment in a clinical trial within 30 days prior to trial entry (except clinical trial SAKK 96/12)

• Concomitant use of other anti-cancer drugs or radiotherapy except for local pain control and GnRH analogues

• Severe or uncontrolled cardiovascular disease

• Acute exacerbations of chronic illnesses, serious infections, or major surgery within 4 weeks before expected start of treatment

• ECG abnormalities of Q-wave infarction, unless identified = 6 months prior to registration or QTc interval >480 msec

• Known gastrointestinal (GI) disease or GI procedure that could interfere with the GI absorption or tolerance of ODM-201

• Known hypersensitivity to trial drug or to any component of the trial drug

• Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications.

Related Conditions & MeSH terms

• Prostate Cancer
• Prostate Cancer Metastatic
• Prostatic Neoplasms

Intervention

Drug:
• ODM-201
ODM-201 will be given at a dose of 600 mg BID orally on a continuous basis.

Other:
• Placebo
Placebo will be given at a dose of 600 mg BID orally on a continuous basis.

Locations

Country	Name	City	State
France	Institut Bergonié	Bordeaux
France	Centre Oscar Lambret	Lille
France	Centre de lutte contre le cancer Léon Bérard	Lyon
France	Centre Eugène Marquis	Rennes
Italy	European Institute of Oncology (EIO)	Milano
Italy	Istituto Nazionale dei Tumori - IRCCS Fondazione	Milano
Italy	Istituto Nazionale dei Tumori - IRCCS Fondazione Pascale S.C.	Napoli
Italy	AOU "Maggiore della Carità" di S.C. di Oncologia	Novara
Italy	AOU San Luigi Gonzaga	Orbassano
Italy	AO San Camillo and Forlanini Hospitals	Roma
Italy	Presidio Ospedaliero Santa Chiara	Trento
Italy	Azienda Ospedaliera Universitaria Integrate Verona (AOUI)	Verona
Spain	Hospital de Torrecárdenas	Almería
Spain	Hospital Universitario Infanta Cristina	Badajoz
Spain	Hospital Clinic Barcelona	Barcelona
Spain	Consorcio Hospitalario Provincial de Castellon	Castellón De La Plana
Spain	Hospital Universitario San Cecilio	Granada
Spain	Hospital Univ. de Guadalajara	Guadalajara
Spain	Centro Integral Oncológico Clara Campal - Hospital Universitario HM Sanchinarro	Madrid
Spain	Hospital Universitario Puerta de Hierro-Majadahonda	Majadahonda
Spain	Hospital General Universitario Morales Meseguer	Murcia
Spain	Complejo Hospital Universitario de Santiago de Compostela	Santiago De Compostela
Switzerland	Kantonsspital Baden	Baden
Switzerland	Istituto Oncologico della Svizzera Italiana (IOSI)	Bellinzona
Switzerland	Kantonsspital Graubuenden	Chur
Switzerland	Hôpital Fribourg HFR	Fribourg
Switzerland	Kantonsspital Liestal	Liestal
Switzerland	Fondazione Oncologia / Oncologia ematologia	Locarno
Switzerland	Kantonsspital Muensterlingen	Münsterlingen
Switzerland	Hôpital du Valais (Sion et Martigny)	Sion
Switzerland	Kantonsspital - St. Gallen	St. Gallen
Switzerland	Spital STS AG	Thun

Sponsors (1)

Lead Sponsor	Collaborator
Swiss Group for Clinical Cancer Research

Countries where clinical trial is conducted

France,  Italy,  Spain,  Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Radiographic progression-free survival (rPFS) at 12 weeks	Radiographic progression-free survival is defined as the time from treatment start to radiographic disease progression or death from any cause, whichever occurs earlier.	At 12 weeks after treatment start
Secondary	Radiographic progression-free survival (rPFS)	Radiographic progression-free survival is defined as the time from treatment start to radiographic disease progression or death from any cause, whichever occurs earlier.	Every 12 weeks until disease progression (estimated up to 1 year)
Secondary	Time to PSA progression	PSA progression is defined as: In case PSA levels had not decreased under treatment with the study drug: = 25% increase over baseline (last PSA measurement before treatment start) AND an increase in the absolute PSA value of = 5 ng/mL.; In case of PSA response < 50% under treatment with the study drug: = 25% increase over the nadir AND an increase in the absolute PSA value of = 5 ng/mL.; In case of PSA response = 50% under treatment with the study drug: = 50% increase over the nadir AND an increase in the absolute PSA value of = 5 ng/mL	PSA level at baseline and every 4 weeks until disease progression (estimated up to 1 year)
Secondary	Time to symptomatic/clinical progression	Symptomatic/clinical progression is defined by one of the following: Occurrence of a SRE due to bone metastases, defined as pathologic fracture, spinal cord compression, palliative radiation to bone, or surgery to bone; Treating physician decides for intervention due to new disease related complications (e.g., urinary obstruction, hydronephrosis)	treatment start to the time point of symptomatic/clinical progression (estimated up to 1 year)
Secondary	Event-free survival	Event-free survival is defined as the time from treatment start until the event of interest.	treatment start until the event of interest (estimated up to 1 year)
Secondary	Overall survival	Overall survival is defined as the time from treatment start until death from any cause.	time from trial randomization to the date of death from any cause (estimated up to 6 years)
Secondary	PSA response (30%, 50%, 90% and best)	30% PSA response is defined as a decrease in PSA level of at least 30% (compared to baseline PSA).; 50% PSA response is defined as a decrease in PSA level of at least 50% (compared to baseline PSA).; 90% PSA response is defined as a decrease in PSA level of at least 90% (compared to baseline PSA).; Best PSA response is defined as the percentage of change in PSA from baseline to the maximum decline in PSA at any point under treatment. If there is a steady increase after baseline, the best response is defined as the percentage of change in PSA from baseline to the minimum increase in PSA at any point under treatment. Baseline is defined as the latest recorded measurement prior to the first dose of trial treatment.	PSA level at baseline and every 4 weeks until disease progression (estimated up to 1 year)